Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer

2.50
Hdl Handle:
http://hdl.handle.net/10541/85228
Title:
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer
Authors:
Borghaei, Hossein; Alpaugh, Katherine; Hedlund, Gunnar; Forsberg, Goran; Langer, Corey J; Rogatko, Andre; Hawkins, Robert E; Dueland Svein; Lassen, Ulrik; Cohen, Roger B
Affiliation:
Chrisite Research Centre, Manchester, United Kingdom
Citation:
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer. 2009, 27(25): 4116-4123 J Clin Onc
Journal:
Journal of Clinical Oncology
Issue Date:
2009
URI:
http://hdl.handle.net/10541/85228
DOI:
10.1200/JCO.2008.20.2515
Type:
Article
Language:
en
ISSN:
0732183X; 15277755
Appears in Collections:
All Paterson Institute for Cancer Research; Medical Oncology

Full metadata record

DC FieldValue Language
dc.contributor.authorBorghaei, Hosseinen
dc.contributor.authorAlpaugh, Katherineen
dc.contributor.authorHedlund, Gunnaren
dc.contributor.authorForsberg, Goranen
dc.contributor.authorLanger, Corey Jen
dc.contributor.authorRogatko, Andreen
dc.contributor.authorHawkins, Robert Een
dc.contributor.authorDueland Sveinen
dc.contributor.authorLassen, Ulriken
dc.contributor.authorCohen, Roger Ben
dc.date.accessioned2009-11-03T14:22:36Z-
dc.date.available2009-11-03T14:22:36Z-
dc.date.issued2009-
dc.identifier.citationPhase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer. 2009, 27(25): 4116-4123 J Clin Oncen
dc.identifier.issn0732183X-
dc.identifier.issn15277755-
dc.identifier.doi10.1200/JCO.2008.20.2515-
dc.identifier.urihttp://hdl.handle.net/10541/85228-
dc.language.isoenen
dc.subjectAdvanced Canceren
dc.subjectNon-Small-Cell Lung Canceren
dc.subjectABR-217620en
dc.subjectDose Escalationen
dc.titlePhase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung canceren
dc.typeArticleen
dc.contributor.departmentChrisite Research Centre, Manchester, United Kingdomen
dc.identifier.journalJournal of Clinical Oncologyen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.